Lee Kaeng W, Lip Gregory Y
Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK.
Blood Coagul Fibrinolysis. 2003 Oct;14(7):605-25. doi: 10.1097/01.mbc.0000061355.73802.ea.
The acute coronary syndromes (ACS), which include unstable angina, non-ST-segment and ST-segment elevation acute myocardial infarction, all share common pathophysiology processes that are characterized by coronary plaque disruption with superimposed thrombus formation, leading to myocardial ischaemia. A greater understanding of these processes has enable us to correlate the abnormalities in arterial vessel wall substrates ('vessel abnormalities'), rheologic and biomechanical conditions ('abnormal flow'), and blood thrombogenicity ('abnormal blood constituents') to the contribution of coronary plaque disruption and subsequent thrombosis, with the basic concepts of Virchow's triad for thrombus formation (thrombogenesis) described about 150 years ago. This improved understanding has led to the identification of newer therapeutic targets and, hence, novel pharmacological agents targeting different components of Virchow's triad, particularly in altering thrombus formation and plaque vulnerability.
急性冠状动脉综合征(ACS),包括不稳定型心绞痛、非ST段抬高型和ST段抬高型急性心肌梗死,都具有共同的病理生理过程,其特征是冠状动脉斑块破裂并伴有血栓形成,导致心肌缺血。对这些过程的更深入了解使我们能够将动脉血管壁底物异常(“血管异常”)、流变学和生物力学状况(“血流异常”)以及血液血栓形成性(“血液成分异常”)与冠状动脉斑块破裂及随后血栓形成的作用联系起来,这与大约150年前描述的血栓形成(血栓形成过程)的魏尔啸三要素的基本概念相关。这种认识的提高导致了新治疗靶点的确定,从而出现了针对魏尔啸三要素不同成分的新型药物,特别是在改变血栓形成和斑块易损性方面。